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OBJECTIVE—To describe and compare the associations of serum lipoproteins and apolipo-
proteins with diabetic retinopathy.
RESEARCH DESIGN AND METHODS—This was a cross-sectional study of 224 di-
abeticpatients(85type1and139type2)fromadiabetesclinic.Diabeticretinopathywasgraded
from fundus photographs according to the Airlie House Classiﬁcation system and categorized
into mild, moderate, and vision-threatening diabetic retinopathy (VTDR). Serum traditional
lipids (total, LDL, non–HDL, and HDL cholesterol and triglycerides) and apolipoprotein AI
(apoAI), apolipoprotein B (apoB), and the apoB-to-apoAI ratio were assessed.
RESULTS—Diabeticretinopathywaspresentin133(59.4%)individuals.Afteradjustment for
age, sex, diabetes duration, A1C, systolic blood pressure, and diabetes medications, the HDL
cholesterol level was inversely associated with diabetic retinopathy (odds ratio 0.39 [95% CI
0.16–0.94], highest versus lowest quartile; Ptrend = 0.017). The ApoAI level was inversely asso-
ciated with diabetic retinopathy (per SD increase, 0.76 [95% CI 0.59–0.98]), whereas apoB (per
SD increase, 1.31 [1.02–1.68]) and the apoB-to-apoAI ratio (per SD increase, 1.48 [1.13–1.95])
were positively associated with diabetic retinopathy. Results were similar for mild to moderate
diabetic retinopathy and VTDR. Traditional lipid levels improved the area under the receiver
operating curve by 1.8%, whereas apolipoproteins improved the area by 8.2%.
CONCLUSIONS—ApoAI and apoB and the apoB-to-apoAI ratio were signiﬁcantly and in-
dependently associated with diabetic retinopathy and diabetic retinopathy severity and im-
proved the ability to discriminate diabetic retinopathy by 8%. Serum apolipoprotein levels
may therefore be stronger biomarkers of diabetic retinopathy than traditional lipid measures.
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D
iabetic retinopathy remains the lead-
ing cause of morbidity and disability
in people with diabetes (1). Whereas
diabetes duration, hyperglycemia, and hy-
pertension are established diabetic retinop-
athy risk factors, the current understanding
of other risk factors for diabetic retinopathy
remains poor (2,3).
There iscontroversy regarding the role
of lipids in the pathogenesis of diabetic
retinopathy (4–6). Data from the Diabetes
Control and Complications Trial (DCCT)
showedthattraditionalmeasuresofserum
lipids (e.g., triglycerides) were positively
associated with the risk of diabetic reti-
nopathy in type 1 diabetes (6). However,
other studies have not consistently shown
similar associations (4,7). Recent data
from the Fenoﬁbrate Intervention and
EventLoweringinDiabetes(FIELD)Study
indicated that fenoﬁbrate, a lipid-altering
medication,reduceddiabeticretinopathy
progression and the need for laser treat-
ment in type 2 diabetes (7). This beneﬁt
was unrelated to serum lipid levels, with
unclear underlying mechanisms.
Recently,therehasbeenaninterestin
the relationship of apolipoprotein AI
(apoAI) and apolipoprotein B (apoB)
with diabetic retinopathy (5,8,9). ApoAI
isan HDLconstituentand apoBispresent
in VLDL, intermediate-density lipopro-
tein (IDL), LDL, and lipoprotein(a), and
both apolipoproteins are not affected by
prandialstatus (10).Because apoAI better
reﬂects lipid accumulation in peripheral
tissues (8) and apoB ispresent in the retina
of human eyes with diabetic retinopathy
(11), they may be more directly relevant
to the biophysiological changes associated
with diabetic retinopathy than the tradi-
tionallipids(e.g.,HDLandLDLcholesterol
and triglycerides) (10). However, the ex-
tent to which apolipoprotein measures are
useful to identify individuals at risk of di-
abetic retinopathy remains unknown. In
this study we aimed to evaluate and com-
pare the associations of apolipoproteins
andtraditionallipidproﬁleswithdiabetic
retinopathy in adults with diabetes.
RESEARCH DESIGN AND
METHODS—This was a clinic-based
observational study.W ec o n s e c u t i v e l y
recruited 224 Caucasians with diabetes
aged18–70years(85withtype1diabetes
and 139 with type 2 diabetes) between
October 2006 and April 2008 from the
eye clinics at the International Diabetes
Institute, Melbourne, Victoria, Australia
(12). Participants were excluded if they
had a history of epilepsy or glaucoma,
had undergone previous vitreal surgery,
and/orhadacataractonexamination.The
study followed the tenets of the Declara-
tion of Helsinki and was approved by the
Institute ethics committee, with written
informed consent obtained from each
participant.
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Pathophysiology/Complications
ORIGINAL ARTICLEAssessment of diabetic retinopathy
Participants had a standardized clinical
examination and retinal photography.
Diabetic retinopathy was graded from
the digital retinal photographs at the
Retinal Vascular Imaging Centre, Centre
for Eye Research Australia by graders
masked to participants’ clinical details. A
diabeticretinopathyseverityscorewasas-
signed for each eye according to the mod-
iﬁed Airlie House Classiﬁcation system
(13). We deﬁned “no diabetic retinopa-
thy” as levels 10–12, mild nonproliferative
diabetic retinopathy (NPDR) as levels 14–
20, moderate NPDR as levels 31 and 41,
and severe NPDR and proliferative dia-
betic retinopathy (PDR) as levels 51–80.
Any diabetic retinopathy was deﬁned as
levels 14–80. Macular edema was deﬁned
as present or absent and classiﬁed as with
or without clinically signiﬁcant macular
edema (CSME). Vision-threatening dia-
betic retinopathy (VTDR) was deﬁned to
include severe NPDR, PDR, and CSME.
Blood chemistry
Fasting(.8h)bloodsamplesweredrawn
from participants at local pathology cen-
ters to assess fasting blood glucose level,
serumlipids(total,HDL,andLDLcholes-
terol and triglycerides) and apolipopro-
tein (apoAI and apoB) levels, and A1C
within 2 weeks of eye examinations.
Non–HDL cholesterol was calculated by
total cholesterol minus HDL cholesterol.
LDL cholesterol was measured using an
LDL cholesterol direct assay. In addition,
on the day of eye examinations, venous
bloodsamplesweredrawnfromeachpar-
ticipant, centrifuged (Heraeus-Labofuge
400R, 1000g,1 0m i n ,4 ° C ) ,a n dt h e na l i -
quoted into polypropylene tubes. All ali-
quots were initially stored (220°C) at the
International Diabetes Institute and sub-
sequently (within 2 weeks) were trans-
ferred on dry ice to storage at 280°C.
Serum apoAI and apoB were measured
later on these samples using rate immu-
nonephelometry (Dade Behring BN II
Nephelometer; Siemens Healthcare Diag-
nostics, Eschborn, Germany) with kits
f r o mt h es a m ec o m p a n ya tt h eD e p a r t -
ment of Medicine, the University of
Melbourne, St. Vincent’sH o s p i t a l( M e l -
bourne, VIC, Australia). Intra-assay coef-
ﬁcients of variation for apoAI and apoB
were 2.2 and 1.9%, respectively, and in-
ter-assay coefﬁcients of variation were 5.7
and 2.4%, respectively.
Assessment of other risk factors
Allparticipantsunderwentastandardized
clinical examination and interview using
a detailed questionnaire to obtain infor-
mation including past medical history,
current cigarette smoking status, and the
useofantihypertensivemedications,lipid-
lowering medications, and oral hypogly-
cemic agents.Hypertensionwasdeﬁnedas
systolicbloodpressure(SBP)$140mmHg,
diastolicbloodpressure(DBP)$90mmHg,
orcurrentuseofantihypertensivemedica-
tions. Height and weight were measured
to determine BMI.
Statistical analysis
Analyses were performed using Inter-
cooled Stata (version 10.1 for Windows;
StataCorp, College Station, TX). Baseline
characteristics of participants with and
without diabetic retinopathy were com-
pared using a x
2 test for proportions,
t test, or Mann-Whitney U test for means.
Serum lipid and apolipoprotein variables
were assessed categorically (in quartiles)
and continuously (per SD change). An in-
dividual’s diabetic retinopathy level was
based on the diabetic retinopathy level
of the worse eye. Logistic regression was
used to assess the association between se-
rum lipids and apolipoproteins and dia-
betic retinopathy. Multinomial and
ordered logistic regression models were
performed to assess associations between
serum lipids or apolipoproteins and
diabetic retinopathy severity categories
(mild and moderate NPDR and VTDR).
We initially adjusted for age and sex
(model 1) and in addition for diabetes
duration, A1C, SBP, BMI, use of diabetes
medications, use of lipid-lowering medi-
cations, and insulin use (model 2). Cova-
riables included in the models were either
continuous (per SD changes for age, SBP,
and BMI; per year for duration; and per
percentage for A1C) or categorical. We
constructed models for diabetic retinopa-
thy prevalence containing either tradi-
tional lipids or apolipoproteins in the
models and used the receiver operator
characteristic (ROC) curve to compare
the discrimination ability of these models.
Area under the ROC curve (AUC) and the
percentage of the incremental changes in
AUC to models with age, sex, duration of
diabetes, A1C, and SBP were assessed.
RESULTS—Of the 224 diabetic study
participants, 13.8% (31) had mild NPDR,
22.3% (50) had moderate NPDR, and
23.3% (52) had VTDR. Participants with
diabetic retinopathy had longer diabetes
duration, higher A1C, and higher SBP
levels than those without diabetic reti-
nopathy (Table 1). Mean levels of tradi-
tional lipids were not signiﬁcantly
different between participants with and
Table 1—Baseline characteristics of 224 participants with diabetes, according to
retinopathy status
Characteristics
Retinopathy status
P value* No Yes
n 95 129
Male sex 55.8 62.0 0.35
Current cigarette smoker 58.1 50.4 0.11
Use of insulin 57.9 71.3 0.037
Use of oral hypoglycemic agents 53.7 55.8 0.75
Use of lipid-lowering medication 46.3 58.1 0.080
Age (years) 58 (49, 66) 60 (52, 66) 0.43
BMI (kg/m
2) 29.5 6 5.6 31.1 6 6.6 0.070
SBP (mmHg) 125.2 6 13.1 130.1 6 15.1 0.011
Duration of diabetes (years) 10 (6, 17) 18 (10, 24) ,0.001
A1C (%) 7.6 6 1.7 8.0 6 1.2 0.022
Cholesterol (mmol/L) 4.7 6 1.1 4.5 6 1.1 0.47
HDL cholesterol (mmol/L) 1.5 6 0.4 1.3 6 0.5 0.056
Non–HDL cholesterol (mmol/L) 3.3 6 1.0 3.2 6 1.1 0.85
LDL cholesterol (mmol/L) 2.5 6 0.7 2.5 6 0.9 0.99
Triglyceride (mmol/L) 1.3 (0.9, 1.9) 1.3 (0.9, 1.9) 0.50
ApoAI (g/L) 1.5 6 0.2 1.4 6 0.3 0.001
ApoB (g/L) 0.8 6 0.2 0.9 6 0.3 0.015
ApoB-to-apoAI ratio 0.6 6 0.2 0.7 6 0.2 ,0.001
Data are %, mean 6 SD, or median (25th, 75th percentile). *P values were obtained using a x
2 test (cate-
gorical), a t test (continuous and normally distributed), or the Mann-Whitney U test (continuous and
skewed), comparing diabetic participants with and without retinopathy.
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Sasongko and Associateswithout diabetic retinopathy. The serum
apoAI level was lower, and both serum
apoB and the apoB-to-apoAI ratio were
higher in participants with diabetic reti-
nopathy than in those without diabetic
retinopathy (P = 0.001, P = 0.015, and
P , 0.001 consecutively) (Table 1).
After adjustment for age and sex,
longer diabetes duration, higher A1C,
and higher SBP levels were associated
with increasing severity of diabetic reti-
nopathy (Ptrend , 0.0001, 0.004, and
0.011, respectively) (Supplementary
Table A1). Table 2 shows associations be-
tween serum lipids, apolipoproteins, and
diabetic retinopathy. After adjustment for
all covariables in model 2, HDL choles-
terol levels were inversely associated
with any diabetic retinopathy (odds ratio
[OR] 0.39 [95% CI 0.16–0.94]; compar-
ing the highest with the lowest quartile,
Ptrend = 0.017). Per SD increase in apoAI
(0.76 [0.59–0.98]), apoB (1.31 [1.02–
1.68]), or the ratio of apoB-to-apoAI ratio
(1.48 [1.13–1.95]) was strongly associ-
atedwithdiabeticretinopathy.Additional
adjustmentfor HDL cholesterol levels did
not alter the associations of apolipopro-
teins with diabetic retinopathy.
Table 3 shows associations of serum
lipids or apolipoproteins with diabetic
retinopathy severity. After adjustment
for all covariables (model 2), per SD in-
crease in apoAI was associated with a re-
duced likelihood of having more severe
diabetic retinopathy levels (Ptrend =
0.001). Likewise, increasing levels of
apoB (Ptrend =0 . 0 2 )a n dt h ea p o B - t o -
apoAI ratio (Ptrend = 0.001) were associ-
ated with increasing diabetic retinopathy
severity levels. In supplementary analyses
stratifying VTDR into severe NPDR (n =
17), PDR (n = 28), and CSME (n = 7), the
association between apoAI and diabetic
retinopathy severity remained signiﬁcant
(Ptrend = 0.02). However, the association
between apoB (Ptrend = 0.06) or the apoB-
to-apoAI ratio (Ptrend = 0.05) and diabetic
retinopathy severity became marginally
nonsigniﬁcant (Supplementary Table
A2). Further stratiﬁcation by sex and di-
abetes type showed that ﬁndings were
largely similar in men and women (Sup-
plementaryTablesA3andA5)andintype
1 and type 2 diabetes (Supplementary
Tables A4, A6, and A7), except for the
association between HDL cholesterol
and diabetic retinopathy.
Table 4 shows the AUC for predict-
ing diabetic retinopathy with traditional
lipids or apolipoproteins in addition to
the established diabetic retinopathy risk
Table 2—Associations of serum lipids with any diabetic retinopathy
Serum lipids
%o f
events
Any retinopathy
Model 1* P value Model 2† P value
Cholesterol (mmol/L)
1st quartile, ,3.8 16.4 1.00 1.00
2nd quartile, 3.8-4.5 12.8 0.91 (0.53–1.57) 0.73 (0.40–1.35)
3rd quartile, 4.5-5.2 14.6 1.02 (0.59–1.76) 0.88 (0.47–1.66)
4th quartile, $5.2 14.2 1.03 (0.60–1.78) 0.82* 0.90 (0.47–1.74) 0.89*
Per SD increase (1.1) 0.94 (0.78–1.14) 0.54 0.91 (0.72–1.14) 0.40
HDL cholesterol (mmol/L)
1st quartile, ,0.9 21.2 1.00 1.00
2nd quartile, 0.9-1.3 16.4 0.84 (0.40–1.75) 0.80 (0.34–1.89)
3rd quartile, 1.3-1.9 13.1 0.46 (0.22–0.95) 0.37 (0.15–0.86)
4th quartile, $1.9 12.0 0.39 (0.19–0.79) 0.003* 0.39 (0.16–0.94) 0.017*
Per SD decrease (0.5) 0.84 (0.66–1.08) 0.182 0.94 (0.71–1.24) 0.44
Non–HDL cholesterol
(mmol/L)
1st quartile, ,1.9 16.4 1.00 1.00
2nd quartile, 1.9-2.4 13.1 0.68 (0.34–1.35) 0.65 (0.30–1.42)
3rd quartile, 2.4-2.9 16.1 1.13 (0.55–2.32) 0.93 (0.42–2.06)
4th quartile, $2.9 15.0 0.95 (0.47–1.92) 0.75* 0.70 (0.29–1.65) 0.61*
Per SD increase (0.8) 1.00 (0.79–1.29) 0.96 0.87 (0.65–1.18) 0.38
LDL cholesterol (mmol/L)
1st quartile, ,1.9 14.9 1.00 1.00
2nd quartile, 1.9-2.4 18.2 1.56 (0.77–3.16) 1.20 (0.52–2.76)
3rd quartile, 2.4-2.9 10.9 0.71 (0.34–1.46) 0.43 (0.18–1.06)
4th quartile, $2.9 14.9 1.31 (0.63–2.71) 0.95* 1.07 (0.45–2.53) 0.67*
Per SD increase (0.8) 1.12 (0.86–1.46) 0.40 1.07 (0.77–1.48) 0.68
Triglyceride (mmol/L)
1st quartile, ,0.9 18.5 1.00 1.00
2nd quartile, 0.9-1.3 13.1 1.00 (0.59–1.72) 0.91 (0.50–1.66)
3rd quartile, 1.3-1.9 12.2 0.77 (0.45–1.31) 0.73 (0.38–1.41)
4th quartile, $1.9 14.4 1.03 (0.60–1.76) 0.82* 0.90 (0.47–1.73) 0.65*
Per SD increase (1.1) 0.98 (0.81–1.20) 0.88 0.95 (0.75–1.19) 0.65
ApoAI (g/L)
1st quartile, ,0.9 19.2 1.00 1.00
2nd quartile, 0.9-1.3 13.9 0.45 (0.25–0.82) 0.37 (0.19–0.72)
3rd quartile, 1.3-1.9 13.7 0.39 (0.22–0.69) 0.48 (0.24–0.96)
4th quartile, $1.9 10.6 0.26 (0.15–0.48) ,0.001* 0.33 (0.16–0.69) 0.015*
Per SD decrease (0.3) 0.67 (0.54–0.83) ,0.001 0.76 (0.59–0.98) 0.034
ApoB (g/L)
1st quartile, ,0.9 11.3 1.00 1.00
2nd quartile, 0.9-1.3 15.0 1.90 (1.10–3.27) 2.10 (1.15–3.82)
3rd quartile, 1.3-1.9 15.0 1.92 (1.14–3.31) 1.89 (1.03–3.43)
4th quartile, $1.9 16.4 2.69 (1.53–4.73) 0.001* 2.69 (1.39–5.20) 0.005*
Per SD increase (0.3) 1.36 (1.10–1.54) 0.004 1.31 (1.02–1.68) 0.035
ApoB-to-apoAI ratio
1st quartile, ,0.9 11.8 1.00 1.00
2nd quartile, 0.9-1.3 12.7 1.23 (0.72–2.09) 0.99 (0.55–1.80)
3rd quartile, 1.3-1.9 15.3 1.86 (1.08–3.20) 1.62 (0.88–2.97)
4th quartile, $ 1.9 17.6 2.84 (1.61–5.00) ,0.001* 2.13 (1.07–4.23) 0.017*
Per SD increase (0.2) 1.60 (1.28–2.00) ,0.001 1.48 (1.13–1.95) 0.005
Data are ORs (95% CI). Each risk factor is in separate models. Model 1: adjusted for age and sex. Model 2:
model 1 plus adjusted for duration of diabetes, A1C, SBP, BMI, use of diabetic medications, lipid-lowering
agents, and insulin. Age, duration of diabetes, A1C, SBP, and BMI were treated as continuous variables.
*Ptrend.
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ApoAI and apoB as biomarkers of retinopathyfactors including age, sex, diabetes dura-
tion, A1C, and SBP. Total percent change
oftheAUC byadditionoftraditional lipids
into the basic model was 1.8%, whereas
additionofapolipoproteinsimprovedthe
AUC by up to 8.2%.
CONCLUSIONS—Serum lipids have
long been proposed to be risk factors for
diabetic retinopathy (4,14), although the
relationship of lipids to diabetic retinop-
athy has been relatively understudied
compared with diabetes duration, A1C,
and blood pressure. Our study demon-
strated that of the traditional lipid mea-
sures, only lower HDL cholesterol was
independently associated with diabetic
retinopathy. However, serum apoAI,
apoB, and the apoB-to-apoAI ratio were
consistently associated with the presence
of diabetic retinopathy and severity of di-
abetic retinopathy, independent of age,
sex, and known diabetic retinopathy
risk factors. Our ﬁndings support previ-
ous evidence that traditional serum lipids
are not strongly or consistently associated
with diabetic retinopathy.
Lipid associations with diabetic reti-
nopathy have been investigated in multi-
ple population-based studies and clinical
trials, but ﬁndings remain inconsistent
(4–6,13,15–17),withnosinglelipidmea-
sure consistently found to be associated
with diabetic retinopathy. For example,
total cholesterol was an independent
risk factor for diabetic retinopathy in the
Chennai Urban Rural Epidemiology
Study(CURES)butwasprotectiveagainst
diabetic retinopathy in the Singapore Ma-
lay Eye Study population (16,17). Similar
to our ﬁndings, data from the DCCT did
not show an association with totalcholes-
terol levels but showed that the HDL cho-
lesterollevelwasinverselyassociatedwith
diabetic retinopathy in type 1 diabetes
(5). Other studies reported that serum
lipids were associated with retinal hard
exudates and diabetic macular edema
only (4,6,15). In contrast, the Multi-Ethnic
Study of Atherosclerosis (MESA) showed
no associations of serum lipids with di-
abetic retinopathy (13). A large random-
izedcontrolledtrialintype2diabetes,the
FIELDStudy,showedthatfenoﬁbrateuse
over 5 years reduced the need for laser
treatment for diabetic retinopathy and
macular edema, although it did not affect
diabetic retinopathy incidence (7).Because
theeffectoffenoﬁbrateondiabeticretinop-
athy was not related to lipid level changes,
its mechanism is not yet clear (18).
Very few reports from the literature
areavailabletocomparewithourﬁndings
regarding apolipoproteins and diabetic
retinopathy. Cross-sectional data from
the DCCT/Epidemiology of Diabetes
Interventions and Complications in
type1diabetesdemonstratedassociations
between diabetic retinopathy and serum
lipoprotein subclass proﬁles (5) and be-
tween apoB, small LDL, and LDL particle
concentration and diabetic retinopathy,
suggesting the role of lipoprotein sub-
classes in the pathogenesis of diabetic
retinopathy (5). Although the exact un-
derlying mechanism is uncertain, we
have strong evidence for the plausibility
of our ﬁndings. HDL is the main vasopro-
tective lipoprotein (19). ApoAI, the main
HDL structural protein that is produced
by the liver and intestine, is essential for re-
verse transport of cholesterol from periph-
eral tissue to the liver. It also has antioxidant
and anti-inﬂammatory effects (19). On the
contrary, apoB is a major structural protein
for VLDL, IDL, and LDL and is responsible
for delivering lipids from the liver and intes-
tine to peripheral tissue. Total apoB levels
mayreﬂectatherogenicpotential(20).There
a r eaf e ws t u d i e ss h o w i n gt h ep r e s e n c eo f
apoAI and apoB in intraocular specimens
(8,9,11). Higher apoAI levels in vitreous
ﬂuid and retinal pigment epithelium among
individuals with diabetes than in those with-
out diabetes (8,9) suggest protective mecha-
nisms within the retina via apoAI against
lipid deposition and inﬂammation-induced
lipotoxicity leading to diabetic retinopathy
(8). Because apoAI has anti-inﬂammatory
and anti-oxidant effects (19) and is also
key to intraretinal lipid transport (21), it is
conceivable that a low level of this pro-
tective agent may promote diabetic reti-
nopathy. Furthermore, evidence showing
increased levels of retinal apoB associated
withgreaterseverityofdiabeticretinopathy
suggests that higher apoB levels, which
may reﬂect higher lipoprotein-related
Table 3—Associations of serum lipids with severity of diabetic retinopathy
Serum lipids (per SD increase) Mild DR Moderate DR VTDR Ptrend
n 31 50 52
Model 1
Cholesterol (1.1) (mmol/L) 1.00 (0.74–1.34) 0.93 (0.72–1.20) 0.93 (0.72–1.19) 0.47
Triglyceride (1.1) (mmol/L) 0.94 (0.68–1.29) 0.88 (0.67–1.16) 1.10 (0.87–1.39) 0.72
HDL cholesterol (0.5) (mmol/L) 0.85 (0.56–1.31) 0.93 (0.68–1.27) 0.77 (0.55–1.06) 0.15
LDL cholesterol (0.8) (mmol/L) 1.00 (0.64–1.57) 1.08 (0.78–1.50) 1.20 (0.88–1.64) 0.26
ApoAI (0.3) (g/L) 0.87 (0.62–1.20) 0.78 (0.59–1.02) 0.48 (0.35–0.64) ,0.001
ApoB (0.3) (g/L) 1.31 (0.95–1.79) 1.33 (1.03–1.72) 1.44 (1.11–1.85) 0.002
ApoB-to-apoAI ratio (0.2) 1.43 (1.03–1.99) 1.45 (1.10–1.90) 1.90 (1.46–2.48) ,0.001
Model 2
Cholesterol (1.1) (mmol/L) 0.97 (0.69–1.36) 0.87 (0.65–1.17) 0.90 (0.66–1.22) 0.19
Triglyceride (1.1) (mmol/L) 0.92 (0.64–1.33) 0.83 (0.61–1.15) 1.06 (0.80–1.40) 0.95
HDL cholesterol (0.5) (mmol/L) 0.90 (0.52–1.54) 0.97 (0.64–1.48) 0.81 (1.54–1.21) 0.30
LDL cholesterol (0.8) (mmol/L) 0.95 (0.58–1.54) 1.04 (0.70–1.53) 1.19 (0.80–1.77) 0.73
ApoAI (0.3) (g/L) 0.86 (0.59–1.27) 0.93 (0.68–1.29) 0.53 (0.38–0.76) 0.001
ApoB (0.3) (g/L) 1.40 (1.00–1.97) 1.27 (0.95–1.71) 1.47 (1.10–1.96) 0.020
ApoB-to-apoAI ratio (0.2) 1.58 (1.07–2.32) 1.22 (0.87–1.69) 1.76 (1.27–2.45) 0.001
Data are ORs (95% CI). Each risk factor is in separate models, calculated per SD increase of serum lipids. Ptrend was calculated using ordered logistic regression.
Model 1: adjusted for age and sex. Model 2: model 1 plus adjusted for duration of diabetes, A1C, SBP, BMI, use of diabetic medications, lipid-lowering agents, and
insulin. Age, duration of diabetes, A1C, SBP, and BMI were treated as continuous variables. DR, diabetic retinopathy.
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inal vascular cells (11).
Although apoAI and HDL or apoB
andLDLarerelated,HDLandLDLdonot
show similar associations with diabetic
retinopathy as apoAI and apoB do. There
are a few reasons to explain why apoAI
and apoB measurements are superior to
HDLandLDLinindividualswithdiabetes
(5,22). First, these apolipoproteins and
HDL cholesterol and LDL cholesterol re-
ﬂect different aspects of lipoprotein com-
position: apolipoproteins are protein
moieties with structural, enzymatic, and
receptor-binding functions, and HDL
cholesterol and LDL cholesterol refer to
the cholesterol lipid content of HDL and
LDL only (10,20). Apolipoproteins occur
in more than one lipoprotein class: apoAI
is found predominantly in HDL, and
there are several apoAI particles per
HDL particle, whereas there is only one
apoBmoietyperparticleofchylomicrons,
VLDL, IDL, LDL, and lipoprotein(a)
(10,20). The use of only HDL and LDL
ignores the signiﬁcant contribution from
otherlipoproteins,and,therefore,itisnot
surprising that HDL cholesterol and LDL
cholesterol were not strongly correlated
with diabetic retinopathy. Second, the di-
abetic milieu induces changes such as
nonenzymatic glycation, oxidation, and
advanced glycation end product modiﬁ-
cation of lipoproteins which may affect
the assay results (23). Similarly, there
m a yb ed i f f e r e n c e si nt h ep r e c i s i o no f
measurement of lipoproteins and poten-
tial for differential effects of sample han-
dling and nonenzymatic glycation and
oxidation on the different assays. On the
contrary, apoAI and apoB levels are more
stable than lipid levels, particularly in indi-
viduals with diabetes, and are not affected
signiﬁcantly by prandial status (5,10).
Our study may have clinical implica-
tions. Although apolipoprotein measure-
ments have not been widely used in
clinical practice, these measures seem to
have distinct and more obvious associa-
tions with diabetic retinopathy than the
traditional lipids. ApoAI, apoB, and the
apoB-to-apoAIratiocoverbothdamaging
and protective lipoprotein pathways. We
showed that serum apoAI, apoB and the
apoB-to-apoAI ratio have better ability to
discriminate the presence and absence
of diabetic retinopathy than traditional
lipids, with an improvement in AUC to
8% compared with less than 2% from
traditionallipids.Theseﬁndingsseemto
support the concept that the regulatory
mechanism of lipid deposition to and
from target tissues (i.e., functions of apoB
and apoAI), particularly the retina, may be
more important than the concentration of
circulating cholesterol in the pathogenesis
of diabetic retinopathy (8,9,11,24).
Thestrengthsofourstudyincludethe
assessment of diabetic retinopathy by
standardizedgrading protocols,andmea-
surement of both traditional lipid and
apolipoprotein levels. Despite the small
sample size, our study sample was typical
of that of other diabetic populations with
diabetic retinopathy, showing strong as-
sociations with A1C level and diabetes
duration. In addition, AUC for estab-
lishedriskfactorsfordiabeticretinopathy
is comparable between MESA (25) and
our present study. We therefore believe,
with good reasons, the generalizability of
our ﬁndings to other diabetic popula-
tions. Limitations are noted. First, the
cross-sectional design of this study does
not provide information as to whether
apoAIandapoBpredictprogressionofdi-
abetic retinopathy. Prospective studies
are needed to assess the temporal se-
quence of these associations. Second,
our diabetic retinopathy grading was
based on only two (optic disc and macu-
lar) ﬁelds rather than on seven ﬁelds of
retinal photographs used by large trials
such as the Early Treatment Diabetic Ret-
inopathy Study (ETDRS). We could have
missed individuals with mild levels of di-
abetic retinopathy and underestimated
diabetic retinopathy prevalence in our
study sample. However, misclassiﬁcation
between case and control subjects will
only bias the associations toward the
null. If seven-ﬁeld retinal photography
were performed in our study, the ob-
served associations would still have been
present, if not stronger. Because of the
relativelysmallsamplesize,nodistinction
was made between type 1 and type 2 di-
abetes in the primary analysis. However,
we have further explored these associa-
tions in subgroups stratiﬁed by diabetes
type.Theseassociationsremainedinboth
subgroups of type 1 and type 2 diabetes
(Supplementary Tables A4 and A6), al-
though it seemed that the associations of
apoB and the apoB-to-apoAI ratio with
diabetic retinopathy were stronger in
type 1 than in type 2 diabetes (Supple-
mentaryTableA6).Third,thenumberof
participantswithCSMEinthisstudywas
verysmall(,5%);thus,wewereunableto
perform a speciﬁca n a l y s i so nC S M E
alone. Finally, the diabetic retinopathy
predictionmodelsandestimateswerede-
r i v e df r o ma n dv a l i d a t e di nt h es a m e
study sample. Conﬁr m a t i o ni no t h e r
studies is needed.
In summary, we report new associa-
tions among serum apolipoproteins
(apoAI, apoB, and the apoB-to-apoAI
ratio) and the presence and severity of
diabetic retinopathy in people with di-
abetes. Concurrently, we showed that
apartfromHDLcholesterol,conventional
serum lipid levels were not signiﬁcantly
associated with diabetic retinopathy. Al-
though more studies are needed to con-
ﬁrm these ﬁndings and to elucidate the
mechanisms for these associations, our
ﬁndings support the fact that these clin-
ically available and feasible apolipopro-
tein measures may be better biomarkers
of diabetic retinopathy than traditional
lipid measures.
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Table 4—Prediction model of traditional
lipids and apolipoproteins for diabetic
retinopathy using AUC
Variables
ROC curve for
diabetic
retinopathy
AUC
% change
in AUC*
Model 1: age, sex,
duration of diabetes,
A1C, SBP 0.690
Model 2†
Cholesterol 0.690 0.0
HDL cholesterol 0.701 1.8
Non–HDL cholesterol 0.684 20.9
LDL cholesterol 0.686 20.6
Triglyceride 0.692 0.3
Traditional lipids‡ 0.701 1.8
Model 2†
ApoAI 0.730 6.6
ApoB 0.723 5.4
ApoB-to-apoAI ratio 0.728 6.2
Apolipoproteins‡ 0.740 8.2
Traditional lipids and
apolipoproteins§ 0.735 7.4
*%increaseinAUC=(AUCmodel22AUCmodel1)/
(AUC model 1) 3100. †Each variable was added
separately to model 1. The AUC of each row is that
of the variable and model 1 only. ‡The combined
change of the AUC for the traditional lipids (total,
HDL,non–HDL,andLDLcholesterolandtriglyceride)
or apolipoproteins (apoAI, apoB, and apoB-to-apoAI
ratio). §The combined change of the AUC for the
traditional lipids and apolipoproteins.
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